81 related articles for article (PubMed ID: 38644473)
21. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
[TBL] [Abstract][Full Text] [Related]
22. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter.
Qiu Z; Zhu W; Meng H; Tong L; Li X; Luo P; Yi L; Zhang X; Guo L; Wei T; Zhang J
Theranostics; 2019; 9(16):4717-4729. PubMed ID: 31367252
[No Abstract] [Full Text] [Related]
23. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
[TBL] [Abstract][Full Text] [Related]
24. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
[TBL] [Abstract][Full Text] [Related]
25. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
Morimura O; Minami T; Kijima T; Koyama S; Otsuka T; Kinehara Y; Osa A; Higashiguchi M; Miyake K; Nagatomo I; Hirata H; Iwahori K; Takimoto T; Takeda Y; Kida H; Kumanogoh A
Biochem Biophys Res Commun; 2017 Jul; 488(4):596-602. PubMed ID: 28526406
[TBL] [Abstract][Full Text] [Related]
26. Disintegrin-like Protein Strategy to Inhibit Aggressive Triple-Negative Breast Cancer.
Limam I; Abdelkarim M; El Ayeb M; Crepin M; Marrakchi N; Di Benedetto M
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569595
[TBL] [Abstract][Full Text] [Related]
27. PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy.
Kelm JM; Pandey DS; Malin E; Kansou H; Arora S; Kumar R; Gavande NS
Mol Cancer; 2023 Mar; 22(1):62. PubMed ID: 36991452
[TBL] [Abstract][Full Text] [Related]
28. Cellular toxicities of gadolinium-based contrast agents used in magnetic resonance imaging.
Akbas E; Unal F; Yuzbasioglu D
J Appl Toxicol; 2023 Jul; 43(7):958-972. PubMed ID: 36394883
[TBL] [Abstract][Full Text] [Related]
29. The Impact of Chemosensitivity on the Outcome of Brain Metastases in Small-Cell Lung Cancer: A Retrospective Analysis.
Ma J; Meng C; Tian J; Ren K; Jia H; Yan M; Xu L; Zhao L
Curr Oncol; 2022 Oct; 29(10):7979-7986. PubMed ID: 36290908
[TBL] [Abstract][Full Text] [Related]
30. Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.
Zhang X; Huo X; Guo H; Xue L
Front Pharmacol; 2022; 13():965244. PubMed ID: 36263120
[TBL] [Abstract][Full Text] [Related]
31. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Izutsu K; Makita S; Nosaka K; Yoshimitsu M; Utsunomiya A; Kusumoto S; Morishima S; Tsukasaki K; Kawamata T; Ono T; Rai S; Katsuya H; Ishikawa J; Yamada H; Kato K; Tachibana M; Kakurai Y; Adachi N; Tobinai K; Yonekura K; Ishitsuka K
Blood; 2023 Mar; 141(10):1159-1168. PubMed ID: 36150143
[TBL] [Abstract][Full Text] [Related]
32. EZH2 Inhibitors: The Unpacking Revolution.
Adema V; Colla S
Cancer Res; 2022 Feb; 82(3):359-361. PubMed ID: 35110396
[TBL] [Abstract][Full Text] [Related]
33. PROTAC targeted protein degraders: the past is prologue.
Békés M; Langley DR; Crews CM
Nat Rev Drug Discov; 2022 Mar; 21(3):181-200. PubMed ID: 35042991
[TBL] [Abstract][Full Text] [Related]
34. Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
Bogart JA; Waqar SN; Mix MD
J Clin Oncol; 2022 Feb; 40(6):661-670. PubMed ID: 34985935
[TBL] [Abstract][Full Text] [Related]
35. Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance.
Mo F; Pellerino A; Soffietti R; Rudà R
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884457
[TBL] [Abstract][Full Text] [Related]
36. Easy or Not-The Advances of EZH2 in Regulating T Cell Development, Differentiation, and Activation in Antitumor Immunity.
Huang J; Zhang J; Guo Z; Li C; Tan Z; Wang J; Yang J; Xue L
Front Immunol; 2021; 12():741302. PubMed ID: 34737746
[TBL] [Abstract][Full Text] [Related]
37. Treatment and Prevention of Brain Metastases in Small Cell Lung Cancer.
Rittberg R; Banerji S; Kim JO; Rathod S; Dawe DE
Am J Clin Oncol; 2021 Dec; 44(12):629-638. PubMed ID: 34628433
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of EZH2 prevents acute respiratory distress syndrome (ARDS)-associated pulmonary fibrosis by regulating the macrophage polarization phenotype.
Bao X; Liu X; Liu N; Zhuang S; Yang Q; Ren H; Zhao D; Bai J; Zhou X; Tang L
Respir Res; 2021 Jul; 22(1):194. PubMed ID: 34217280
[TBL] [Abstract][Full Text] [Related]
39. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
40. Small-cell lung cancer.
Rudin CM; Brambilla E; Faivre-Finn C; Sage J
Nat Rev Dis Primers; 2021 Jan; 7(1):3. PubMed ID: 33446664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
